Clinical trial · Observational
Predictive Value of CEA and ctDNA in Lung Cancer Recurrence
Predictive Value of CEA and ctDNA for Postoperative Recurrence in Patients With High CEA Sensitivity Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperative CEA and MRD in this population are related.This study was carried out to accurately predict the recurrence time, save the time and cost of changing the intervention strategy, and provide more personalized treatment for patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Carcinoma | Lung Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- retrospective cohort
- description
- The clinical information of the population in this cohort was retrospectively collected.
- label
- prospective cohort
- description
- The clinical information of the population in this cohort was prospectively collected.
Primary outcomes (1)
- measure
- Postoperative tumor recurrence or progression
- timeFrame
- 2 years
- description
- If the tumor recurs or progresses within 2 years, it will be marked as 1. If not, it will be marked as 0.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: 1. Preoperative CEA \> 5mg/l 2. MRD testing was conducted before the operation 3. The primary lesion was resected through surgery 4. There should be at least two CEA and MRD follow-up tests within 2 years after the operation 5. Postoperative pathology confirmed it as a malignant lung tumor Exclusion Criteria: 1. Those without available imaging records 2. Patients with a history of malignant tumors within the past five years 3. Patients with secondary lung cancer
References
Publications (0)
Data not yet available